<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00958516</url>
  </required_header>
  <id_info>
    <org_study_id>LEO 29102-C02</org_study_id>
    <secondary_id>EudraCT Number 2009-011177-32</secondary_id>
    <nct_id>NCT00958516</nct_id>
  </id_info>
  <brief_title>Assessment of the Phototoxic Potential of LEO 29102 Cream</brief_title>
  <official_title>A Phase 1 Study Evaluating the Phototoxic Potential of LEO 29102 Cream (2.5 mg/g, 1.0 mg/g, 0.3 mg/g, 0.1 mg/g, 0.03 mg/g) and the Cream Vehicle, Applied on Intact Skin of Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LEO Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LEO Pharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this trial is to evaluate the phototoxic potential of a single application on
      healthy skin of LEO 29102 cream in different doses.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2009</start_date>
  <completion_date type="Actual">October 2009</completion_date>
  <primary_completion_date type="Actual">October 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phototoxic reaction according to the investigator's assessment</measure>
    <time_frame>5 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical scoring and other skin reactions</measure>
    <time_frame>5 days</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Atopic Dermatitis</condition>
  <arm_group>
    <arm_group_label>LEO 29102 cream</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LEO 29102 cream</intervention_name>
    <description>LEO 29102 cream in different doses and the cream vehicle</description>
    <arm_group_label>LEO 29102 cream</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects having understood and signed an informed consent form

          -  Male adults between the age of 18 and 65 years (both inclusive)

          -  Healthy subjects without signs of skin irritation on test areas (erythema, dryness,
             roughness or scaling)

          -  Subjects willing and able to follow all the study procedures and complete the whole
             study

          -  Subjects affiliated to a social security system

        Exclusion Criteria:

          -  Females

          -  Males who are not willing to use a local contraception for the entire duration of the
             study, and refrain from fathering a child within 3 months following the study drug

          -  Systemic treatments which may interfere with the inflammatory reaction (e.g.,
             corticosteroids and other anti-inflammatory drugs) within 2 weeks prior to
             randomisation

          -  Systemic or topical treatments suspected of causing photobiological reactions (e.g.,
             tetracycline, thiazides, fluoroquinolones) within 4 weeks prior to randomisation

          -  Exposure to excessive or chronic UV radiation (i.e., sunbathing, solarium,
             phototherapy) within 4 weeks prior to inclusion or is planned during the study period

          -  Dark pigmentation of the skin or skin type that may, in any way, confound
             interpretation of the study results (skin types V and VI on the Fitzpatrick scale)

          -  Scars, moles, sunburn or other blemishes in the test area which may interfere with
             grading

          -  Any systemic or cutaneous disease on the test area that may confound interpretation of
             the study results (e.g., atopic dermatitis, eczema, psoriasis)

          -  Relevant history of or concurrent photo-induced or photo-aggravated disease (abnormal
             response to sunlight

          -  Subjects with a history of serious allergy, allergic skin rash or known sensitivity to
             any component of the investigational products

          -  Subjects who have received treatment with any non-marketed drug substance (i.e., an
             agent which has not yet been made available for clinical use following registration)
             within the last four (4) weeks before randomisation

          -  Participation in any other current interventional clinical trial based on interview of
             the subject

          -  Previously randomised in this trial

          -  Subjects impossible to contact in case of emergency

          -  Subjects known or, in the opinion of the investigator, are unlikely to comply with the
             Clinical Study Protocol (e.g. alcoholism, drug dependency or psychotic state)

          -  Subjects who are in an exclusion period in the National Biomedical Research Register
             of the French Ministry of Health

          -  Subjects under guardianship, hospitalised in a public or private institution for a
             reason other than research or subject deprived of freedom
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Director International Clinical Development, MD</last_name>
    <role>Study Director</role>
    <affiliation>LEO Pharma</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>LEO Pharma site</name>
      <address>
        <city>St Quentin en Yvelines Cedex</city>
        <zip>78054</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 12, 2009</study_first_submitted>
  <study_first_submitted_qc>August 12, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 13, 2009</study_first_posted>
  <last_update_submitted>October 24, 2013</last_update_submitted>
  <last_update_submitted_qc>October 24, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 25, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>volunteers</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Eczema</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

